GottardisM.M., LamphW.W., ShalinskyD.R., WellsteinA., HeymanR.A.The efficacy of 9-cis retinoic acid in experimental models of cancer. Breast Cancer Res Treat.1996; 38(1): 85–96.
2.
SmitJ.V., de JongE.M., van HooijdonkC.A., OteroM.E., BoezemanJ.B., van de KerkhofP.C.Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. J Am Acad Dermatol.2004 Aug; 51(2): 257–64.).
3.
YamauchiP.S., RizkD., LoweN.J.Retinoid Therapy for Psoriasis. Dermatol Clin.2004; 22(4): 467–76.
4.
SmitJ.V., FranssenM.E., de JongE.M., LambertJ., RoseeuwDl, De WeertJ., YocumR.C., StevensV.J., van De KerkhofP.C.A phase II multicenter clinical trial of systemic bexarotene in psoriasis. J Am Acad Dermatol.2004 Aug; 51(2): 249–56.
5.
BuschC., SiegenthalerG., VahlquistA., NordlinderH., SundelinJ., SaksenaP., ErikssonU.J.Expression of cellular retinoid-binding proteins during normal and abnormal epidermal differentiation. Invest Dermatol.1992; 99(6): 795–802.
6.
SternR.S., LiebmanE.J., VakevaL.Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst.1998 2; 90(17): 1278–84.
7.
NijstenT.E., SternR.S.Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol.2003; 49(4): 644–50.
8.
LebwohlM., TannisC., CarrascoD.Acitretin suppression of squamous cell carcinoma: case report and literature review. J Dermatolog Treat.2003; 14 Suppl 2: 3–6.
9.
van de KerkhofP.C., de RooijM.J.Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance. Br J Dermatol.1997; 136(2): 275–8.
10.
HarwoodC.A., Leedham-GreenM., LeighI.M., ProbyC.M.Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol.2005; 141(4): 456–64.
11.
BavinckJ.N., TiebenL.M., Van der WoudeF.J., TegzessA.M., HermansJ., ter ScheggetJ., VermeerB.J.Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol.1995 Aug; 13(8): 1933–8.
GiannottiB., VanziL., DifonzoE.M., PimpinelliN.The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin. Clin Exp Dermatol.2003; 28 Suppl 1: 33–5.
14.
BerbisP.Acitretine [article in French]. Ann Dermatol Venereol.2001 Jun-Jul; 128(6-7): 737–45.
